Sedation in neonatal emergencies: ¿dexmedetomidine, the ideal agent?
Keywords:
Anesthesia, dexmedetomidine, infant, newborn, sedation, artificial respirationAbstract
Introduction Dexmedetomidine is a highly selective and potent alpha 2 agonist drug with analgesic, amnesic, sedative and sympatholytic properties that make it an important auxiliary agent in emergency procedures. The advantages of dexmedetomidine are unique, it produces conscious sedation and analgesia without respiratory depression. It has been reported to have neuroprotective effects in various models of brain injury, however, there is increasing evidence on organ protective effects against ischemic and hypoxic injury, including cardioprotection and renoprotection. Neuroprotection benefits neonates and delayed cardiac conduction, an adverse effect, may be beneficial for arrhythmias after congenital heart surgery.
Objective: To provide the best scientific evidence of dexmedetomidine in relation to its advantages in the mentioned age group.
Material and methods: A systematic review of the scientific literature published in the period 2015-2020 was carried out. The following sites were searched using the following terms: "anesthesia", "dexmedetomidine", "newborn", "sedation", "mechanical ventilation", "respiratory insufficiency", "pharmacology", "adverse effects" in bases Data: Medline, Minerva Anestesiologica, The Journal of Pediatric Pharmacology and Therapeutics, Anesthesia & Analgesia, Pediatric Critical Care Medicine and Current Opinion in Anaesthesiology.
Results: The best scientific evidence suggests that dexmedetomidine is an agent of great potential in neonatal and pediatric age, for sedation management with preservation of respiratory autonomy, which would make it an ideal agent in this age group.
Conclusions: The theoretical advantages of dexmedetomidine in the target age group make it a highly useful drug; neonates are mostly susceptible to respiratory depression due to opioids or benzodiazepines in sedation due to their still immature anatomical and upper respiratory center variations. Although its safety and efficacy have not been proven with large randomized clinical trials, it is projected as a quality alternative for sedation in the described age group.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
